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Abstract
Background: Among the multiple mechanisms of action of topiramate, AMPA/kainate antagonism
may be particularly interesting for the treatment of disorders characterized by conditioned
cognitive and behavioral cue reactivity.
Case presentation: We report the case of a patient consulting primarily for obesity and cue
triggered snacking, who responded well on topiramate at doses up to 50 mg. Coincidentally he
reported on an improvement of compulsive nonparaphilic sexual behaviors (consumption of
prostitution), which was also strongly triggered by environmental cues. Both addictive behaviors
(snacking and consumption of prostitution) reoccurred after discontinuation of topiramate and
again responded reintroduction of the drug.
Conclusion:  The present case report of topiramate's effect on comorbid obesity and
nonparaphilic addiction could be interpreted as a further indication that topiramate acts on the
common pathway underlying conditioned behaviors and seems to be a treatment of behavioral
disorders associated with environmental cues.
Background
Behaviors with a compulsive and/or addictive component
can characteristically be triggered by environmental cues
[1]. Recent research has highlighted a central role of the
glutamatergic system in mediating this cue reactivity.
The  α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) receptor has been found to mediate the
expression of established addiction [2]. For example.,
AMPA has been found to reinstate drug seeking [3] and
AMPA receptor blocking properties (AMPAR) antagonists
to block reinstatement[4].
The sulfamate derivative, topiramate, has multiple mech-
anisms of action, including AMPA/kainate blocking prop-
erties [5]. Given the role of AMPAR in the expression of
conditioned responses and topiramate's AMPAR-antago-
nistic properties, topiramate's interest in the treatment of
disorders characterized by conditioned cognitive and/or
behavioral responses is suggested [6].
Diverse studies and case reports have recently raised the
interest of topiramate in the treatment of addictive disor-
ders such as alcohol dependence [7,8], opiates [9] and
benzodiazepines withdrawal [10], smoking cessation
(Khazaal et al in press), but also in other disorders charac-
terized by compulsive behavior like binge eating disorder
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[11], bulimia nervosa [12], obesity [13], Tourette's syn-
drome [14], flash-backs and nightmares in PTSD [15],
and self-mutilation behavior [16].
Nonparaphilic sexual addiction has been characterized by
excessive and continued engagement in conventional sex-
ual activities (i.e extra marital affairs, prostitution, por-
nography, compulsive masturbation) despite subjective
distress and negative consequences [17]. Traditional treat-
ment approaches include individual or group CBT and
family therapy. To date, there is no well studied pharma-
cological treatment of nonparaphilic sexual addictions.
Some reports indicate the utility of lithium, tricyclic anti-
depressants, selective serotonine reuptake inhibitors,
nefazodone and atypical antipsychotics and fluoxetine-
naltrexone combination [18-21].
To our knowledge, the effectiveness of topiramate is
reported in a paraphilic[22] as well as in a nonparaphilic
sexual disorder [23]. We are presenting what is believed to
be the first report of topiramate effect on comorbid obes-
ity and nonparaphilic sexual addiction.
The authors obtained written consent from the patient for
publication of this case report.
Case presentation
The patient, a 33 years old, Caucasian, non-smoker,
reported no personal history of substance abuse, gam-
bling or mood or anxiety disorders. He had been married
for two years, did not have any children and worked as an
engineer for the same company for 4 years. He reported a
good quality of marital life and satisfying sexual marital
activities.
He currently consulted for the treatment of obesity (Body
mass index: BMI = 31). He reported three previous dietary
treatments and one cognitive behavioral treatment, which
were unfortunately always immediately followed by
weight gain. He asked for pharmacological treatment of
his obesity.
The assessment of his eating behavior revealed no binge
eating. While he took 3 meals per day, the frequent snacks
(5 to 7 per day) represented half of his daily caloric intake.
The intake of snacks was always triggered by specific cues
(such as specific food stimuli: sweets with vanilla cream or
chocolate and sandwiches with some kind of bread, the
smell of hot bread, some roads, specific food stores...).
The patient provided verbal informed consent based on
disclosure of off-label usage of topiramate for the indica-
tion, the alternative treatments, and expected adverse
events and risks. Topiramate was started at a dosage of 25
mg and then increased after one week to a dosage of 50
mg. He also received three cognitive and behavioral ses-
sions in order to explore specific cues and to determine
their role in his obesity. He was advised to maintain his
mean meals, and snacking reduction and weight loss were
defined as treatment goals.
After one week of topiramate treatment, he has succeeded
in reducing "snacking" to twice a week. He reported that
although he saw the cues he felt less attracted by them,
sometimes even failing to notice them. He did not experi-
ence significant side effects and lost 3.5 kg during the first
month.
What's more, the patient reported an unexpected change
in his sexual behavior. He described for the first time dur-
ing the second month of treatment that he began going to
massage clubs, and street prostitutes 4 years ago which led
him quickly to spend nearly one third of his monthly
income : 3000 Swiss Francs (F). He did not engage in por-
nography nor paraphilic behaviors such as exhibitionism,
voyeurism or pedophilia. Furthermore he did not have
any extra marital sexual relations other than through pros-
titution. He tried many times to stop or reduce this behav-
ior due to shame and feelings of guilt and in order to
reduce his expenses but he could not stop this behavior
for more than one week. The subject reported that seeing
sexual advertisements or passing through streets where
prostitutes work caused in him a feeling of urgency, crav-
ing with an inner tension accompanied by a hot abdomi-
nal sensation and modification in salivation lasting until
his next sexual intercourse with a prostitute. He felt an
attraction to those places, "always returning there as if
drawn by a magnet". Surprisingly, he observed in the sec-
ond week of topiramate treatment that he was in an attrac-
tive area (with many street prostitutes) but did not feel
any urge. He experienced this phenomenon later when
trying to expose himself to habitual cuesnoticing the
places and the signs but feeling less attracted by them and
no longer having the craving nor physical symptoms,
urges and tension. His marital sexual activity remained
unchanged and was perceived as good. He spent no more
than 200 F per month in massage clubs and was satisfied
by this evolution.
After 4 months of treatment, a weight loss of 10.8 kg (BMI
= 27.3) and persistent modification in the sexual addic-
tion, he decided to stop treatment, feeling that he had
more than reached his goals.
Eight weeks after topiramate discontinuation, he con-
sulted again describing a relapse in the compulsive eating
and compulsive prostitute visits, having occurred two
weeks after topiramate cessation, leading to a weight gain
of 3 kg and spending of 2000 F in brothels. Three weeks
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stated a reinstatement of the therapeutic effect within 10
days. He asked for a new topiramate prescription and
remained on the same treatment (topiramate 50 mg/day)
for the following 6 months. His weight remained stable
(BMI = 26.7) and he spent less than 300 F/month for
prostitutes with no relapse to the previous feeling of irre-
pressible attraction of related sexual cues.
Conclusion
For the two problematic behaviors, he reported on a
reduced urge and craving and attraction of environmental
cues after topiramate introduction which allowed him to
reduce considerably these behaviors.
Previous studies using topiramate for treating addictive
behaviors used doses reached 200 mg [7,24]. The prefixed
schedules used by those studies, however, did not allow
the adapted doses to be determined. In our case, we found
a dose as low as 50 mg to be sufficient, in contrast to the
previous report of topiramate's effect on sexual non para-
philic addiction, where 200 mg per day were used.
While a spontaneous remission or a placebo effect cannot
be completely ruled out in the present case, different cri-
teria sustain topiramate efficacy: the previous case reports,
the temporal correlation with the topiramate administra-
tion, the relapse after discontinuation and the responding
after resumption of the treatment, and the absence of any
contributing life event.
The concomitant improvement of eating habits and sex-
ual addiction observed under topiramate corroborate the
hypothesis of topiramate acting on the common pathway
underlying conditioned behaviors. As expected by psy-
chopharmacological data and previous clinical trials on
the treatment of addictive and eating disorders, topiram-
ate seems to be promising medication for treatment of
sexual addiction associated with behavioral cues.
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